The prostate cancer landscape in Europe: Current challenges, future opportunities

Maximilian Marhold; Gero Kramer; Michael Krainer; Clémentine Le Magnen

doi:10.1016/j.canlet.2021.11.033

The prostate cancer landscape in Europe: Current challenges, future opportunities

Cancer Lett. 2022 Feb 1:526:304-310. doi: 10.1016/j.canlet.2021.11.033. Epub 2021 Dec 2.

Authors

Maximilian Marhold¹, Gero Kramer², Michael Krainer³, Clémentine Le Magnen⁴

Affiliations

¹ Division of Oncology, Department for Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: maximilian.marhold@meduniwien.ac.at.
² Department of Urology, Medical University of Vienna, Vienna, Austria.
³ Division of Oncology, Department for Medicine I, Medical University of Vienna, Vienna, Austria.
⁴ Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Switzerland; Department of Urology, University Hospital Basel, Basel, Switzerland.

PMID: 34863887
DOI: 10.1016/j.canlet.2021.11.033

Abstract

Prostate cancer (PCa) is the most common non-cutaneous cancer in men in Europe and is predicted to exhibit declining mortality in the European Union (EU) due to various recent improvements in treatment. The goal of this short review is to give insight into the European treatment landscape of PCa, while focusing on improvements in care.

Keywords: Europe; Prostate cancer; Treatment.

MeSH terms

Europe
Humans
Male
Prostatic Neoplasms / epidemiology*